AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17116670 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (Mycamine)
Number of subjects: 35
Study 17116670 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 35
Study 12766899 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 21
Study 12766899 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 21
Study 10321522 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA-cream therapy
Number of subjects: 12
Study 10321522 — intervention group
Group type: COMPARATOR
Intervention: PUVA-bath therapy
Number of subjects: 12
Study 9185262 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Azithromycin (300 mg artemether + 500 mg azithromycin, followed by 250 mg azithromycin at 24 and 48 hours)
Number of subjects: 60
Study 9185262 — intervention group
Group type: COMPARATOR
Intervention: Artemether-Doxycycline (300 mg artemether + 100 mg doxycycline as initial doses, followed by 100 mg artemether + 100 mg doxycycline at 12 hours later, then 100 mg doxycycline every 12 hours for another 4 days)
Number of subjects: 60
Study 1926059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 100 mg
Number of subjects: 8
Study 1926059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 200 mg
Number of subjects: 8
Study 1926059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 400 mg
Number of subjects: 8
Study 1926059 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 5,000 IU
Number of subjects: 8
Study 1926059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6760652 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin vaginal tablets for 10 days, partners treated with natamycin cream
Number of subjects: 33
Study 6760652 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream for partners
Number of subjects: 33
Study 6760652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and placebo)
Number of subjects: 33
Study 31152113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rude environment (incivility)
Number of subjects: 76
Study 31152113 — intervention group
Group type: COMPARATOR
Intervention: Normal environment (control)
Number of subjects: 76
Study 28215166 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaweed polysaccharides
Number of subjects: 0
Study 28215166 — intervention group
Group type: COMPARATOR
Intervention: Current anti-inflammatory drugs
Number of subjects: 0
Study 25956843 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L‐AmB) inhalation
Number of subjects: 127
Study 25956843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L‐AmB inhalation)
Number of subjects: 127
Study 23614586 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-education package (including a cartoon video)
Number of subjects: 1718
Study 23614586 — intervention group
Group type: COMPARATOR
Intervention: Control package (health-education poster)
Number of subjects: 1718
Study 22066824 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with soy protein based supplementation (RTS-G)
Number of subjects: 40
Study 22066824 — intervention group
Group type: COMPARATOR
Intervention: Resistance training without supplementation (RT-G)
Number of subjects: 40
Study 22066824 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education only (LE-G)
Number of subjects: 40
Study 19749201 — intervention group
Group type: COMPARATOR
Intervention: Impedance cardiography (ICG) measures during supine rest and HUT test.
Number of subjects: 86
Study 19749201 — intervention group
Group type: COMPARATOR
Intervention: Baseline cardiovascular measurements (CI, EDI, LVWI) using ICG.
Number of subjects: 86
Study 16467677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Number of subjects: 12
Study 16467677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Number of subjects: 12
Study 16467677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin 0.3% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Number of subjects: 12
Study 16467677 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin 0.3% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Number of subjects: 12
Study 15849397 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B (CBH)
Number of subjects: 47
Study 15512472 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 56
Study 15512472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine contraceptive device (IUCD)
Number of subjects: 56
Study 9124829 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (intravenous dosages for 10 days)
Number of subjects: 27
Study 9124829 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 27
Study 1425160 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (6-20 IU at bedtime plus oral drugs)
Number of subjects: 38
Study 1425160 — intervention group
Group type: COMPARATOR
Intervention: Placebo-insulin
Number of subjects: 38
Study 6737950 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (12 U hGH/m2 per week)
Number of subjects: 6
Study 6737950 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group (no specific intervention mentioned)
Number of subjects: 6
Study 30393077 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dietary intake assessment using Automated Self‐Administered 24‐Hour Recall; participants reported food intake on 3 nonconsecutive days.
Number of subjects: 37
Study 29762043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 1.6 g/day for 12 weeks
Number of subjects: 37
Study 29762043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 28892575 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole during pregnancy
Number of subjects: 1215
Study 28892575 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel during pregnancy
Number of subjects: 1215
Study 28892575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly albendazole from age 15 months to 5 years
Number of subjects: 1215
Study 28892575 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 1215
Study 28892575 — intervention group
Group type: COMPARATOR
Intervention: Placebo from age 15 months to 5 years
Number of subjects: 1215
Study 25646027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan or temozolomide
Number of subjects: 37
Study 24040856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (0.02 mg×kg‐1×min‐1)
Number of subjects: 60
Study 24040856 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (0.25 μg×kg‐1×min‐1)
Number of subjects: 60
Study 21440548 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF genotype G/G
Number of subjects: 816
Study 21440548 — intervention group
Group type: COMPARATOR
Intervention: EGF genotype A/A
Number of subjects: 816
Study 21440548 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with at least one G allele
Number of subjects: 816
Study 21440548 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF G/G genotype with above-median serum levels of EGF
Number of subjects: 816
Study 21440548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including EGF genotype
Number of subjects: 816
Study 18178070 — intervention group
Group type: EXPERIMENTAL
Intervention: ITRA‐GSMP capsule (50mg itraconazole)
Number of subjects: 8
Study 18178070 — intervention group
Group type: COMPARATOR
Intervention: Sporanox capsule (100mg itraconazole)
Number of subjects: 8
Study 17000452 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pilocarpine (Salagen) four times daily for 12 weeks
Number of subjects: 44
Study 17000452 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 44
Study 14525814 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze inadequate plexus anesthesia
Number of subjects: 65170
Study 14525814 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze difficult emergence from general anesthesia
Number of subjects: 65170
Study 14525814 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze intubation difficulties
Number of subjects: 65170
Study 14525814 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze medication errors
Number of subjects: 65170
Study 11038436 — intervention group
Group type: EXPERIMENTAL
Intervention: Celgene thalidomide capsules (200 mg) under fasted conditions
Number of subjects: 13
Study 11038436 — intervention group
Group type: EXPERIMENTAL
Intervention: Celgene thalidomide capsules (200 mg) with food
Number of subjects: 13
Study 11038436 — intervention group
Group type: EXPERIMENTAL
Intervention: Serral thalidomide tablets (200 mg) under fasted conditions
Number of subjects: 13
Study 9068325 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol
Number of subjects: 20
Study 9068325 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 20
Study 9068325 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling
Number of subjects: 20
Study 8452109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks
Number of subjects: 30
Study 3456377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed lesions
Number of subjects: 14
Study 3456377 — intervention group
Group type: COMPARATOR
Intervention: Control lesions
Number of subjects: 14
Study 30425351 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based specialised palliative care and dyadic psychological intervention
Number of subjects: 258
Study 27211082 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus cholecalciferol (600 mg/d + 200 IU/d)
Number of subjects: 56
Study 27211082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24897082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (intravenously on days 1 and 8)
Number of subjects: 1312
Study 24897082 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (intravenously for at least 3 days, with an option to switch to oral linezolid)
Number of subjects: 1312
Study 24897082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 1312
Study 24897082 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin-linezolid
Number of subjects: 1312
Study 22424015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 384
Study 22424015 — intervention group
Group type: COMPARATOR
Intervention: Vascular brachytherapy (VBT)
Number of subjects: 384
Study 21029622 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Number of subjects: 189
Study 18409107 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (optimal arousal regulation)
Number of subjects: 9
Study 18409107 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (poor arousal regulation)
Number of subjects: 9
Study 18409107 — intervention group
Group type: COMPARATOR
Intervention: Attention control (no biofeedback intervention)
Number of subjects: 9
Study 15889586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-theta neurofeedback
Number of subjects: 24
Study 15889586 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) biofeedback
Number of subjects: 24
Study 15889586 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 24
Study 12610841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath concept (neurodevelopmental treatment)
Number of subjects: 15
Study 12610841 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 15
Study 10826567 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid (ASA) daily
Number of subjects: 18790
Study 10826567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study 10826567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower diastolic BP target groups (< or = 80 mmHg)
Number of subjects: 18790
Study 10826567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower diastolic BP target groups
Number of subjects: 18790
Study 8075614 — intervention group
Group type: EXPERIMENTAL
Intervention: Horacort (2 puffs bd) for 8 weeks in asthma patients
Number of subjects: 47
Study 8075614 — intervention group
Group type: EXPERIMENTAL
Intervention: Horacort (2 puffs bd) for 4 weeks in allergic rhinitis patients
Number of subjects: 47
Study 8075614 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort (control)
Number of subjects: 47
Study 8075614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 47
Study 2561518 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (100 mcg) + TRH (200 mcg) + GHRH 1‐29NH2 (100 mcg) i.v. (Politest 'B')
Number of subjects: 20
Study 2561518 — intervention group
Group type: COMPARATOR
Intervention: LHRH (100 mcg) + TRH (200 mcg) + Human Insulin (0.1 UI/kg) i.v. (Politest 'A')
Number of subjects: 20
Study 2561518 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1‐29NH2 (100 mcg) i.v. (GHRH-TEST)
Number of subjects: 20
Study 998673 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy with pelvic lymph node dissection
Number of subjects: 446
Study 998673 — intervention group
Group type: COMPARATOR
Intervention: Full-course radiation therapy
Number of subjects: 446
Study 998673 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 446
Study 31863582 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (film about quitting smoking)
Number of subjects: 53
Study 31863582 — intervention group
Group type: COMPARATOR
Intervention: Attention-control film (women talking about living with HIV)
Number of subjects: 53
Study 30580572 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DKK1 concentration
Number of subjects: 5165
Study 30580572 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in DKK1 and levels at 1 month
Number of subjects: 5165
Study 30580572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 5165
Study 28350714 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-transportable carbohydrate (2:1 glucose-fructose)
Number of subjects: 74
Study 28350714 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric carbohydrate (glucose/maltodextrin only)
Number of subjects: 74
Study 26231225 — intervention group
Group type: EXPERIMENTAL
Intervention: I-DECIDE website
Number of subjects: 0
Study 26231225 — intervention group
Group type: COMPARATOR
Intervention: Comparator website (basic relationship and safety advice)
Number of subjects: 0
Study 23059506 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 787
Study 23059506 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 787
Study 20844068 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized ground ferric pyrophosphate (MGFePP)
Number of subjects: 142
Study 20844068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iron edetate (NaFeEDTA)
Number of subjects: 142
Study 20844068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 18379224 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (100% < or = lactate threshold (LT) training)
Number of subjects: 18
Study 18379224 — intervention group
Group type: COMPARATOR
Intervention: MIX (70% training at < or = LT and 30% at halfway (50%Delta) between the V O2 at LT and V O2peak)
Number of subjects: 18
Study 18379224 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW and MIX
Number of subjects: 18
Study 18379224 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW
Number of subjects: 18
Study 16375890 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)‐THC 5 mg orally
Number of subjects: 0
Study 16375890 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.02 mg/kg intravenously
Number of subjects: 0
Study 16375890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12576168 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 1422
Study 10976542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% caprylocaproyl macrogolglycerides
Number of subjects: 12
Study 9190776 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpreter assisted counseling on HIV prevention
Number of subjects: 248
Study 9190776 — intervention group
Group type: COMPARATOR
Intervention: No systematic counseling (control group)
Number of subjects: 248
Study 1437958 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Number of subjects: 110
Study 1437958 — intervention group
Group type: COMPARATOR
Intervention: 4 hours bed rest
Number of subjects: 110
Study 3083785 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC+5‐FU+lentinan (LNT)
Number of subjects: 166
Study 3083785 — intervention group
Group type: COMPARATOR
Intervention: MMC+5‐FU
Number of subjects: 166
Study 31014365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation associated with inspiratory muscle training without any load (PRWIMT)
Number of subjects: 60
Study 31014365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation associated with inspiratory muscle training with a linear load (PRIMTLL)
Number of subjects: 60
Study 31014365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation associated with inspiratory muscle training with isocapnic voluntary hyperpnea (PRIMTIVH)
Number of subjects: 60
Study 29554497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 493
Study 29554497 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 493
Study 29554497 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine (10-20 mg/day) and Agomelatine (25-50 mg/day)
Number of subjects: 493
Study 26692296 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (forming if-then plans)
Number of subjects: 348
Study 26692296 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation (values essay)
Number of subjects: 348
Study 26692296 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation with social value affirmation
Number of subjects: 348
Study 25512268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPostC)
Number of subjects: 46
Study 22967863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minocycline and artificial tears
Number of subjects: 60
Study 22967863 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears only
Number of subjects: 60
Study 20884700 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted empowerment strategy (decision aid, nurse support, reimbursement offer)
Number of subjects: 308
Study 20884700 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care for in vitro fertilisation)
Number of subjects: 308
Study 17874331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1,600 mg
Number of subjects: 125
Study 17874331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 2,400 mg
Number of subjects: 125
Study 17874331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 3,200 mg
Number of subjects: 125
Study 17874331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 15654690 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (knee extension and leg-press exercises) performed three times per week for 14 weeks
Number of subjects: 0
Study 12232493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur baths
Number of subjects: 38
Study 12232493 — intervention group
Group type: COMPARATOR
Intervention: Control (spa therapy)
Number of subjects: 38
Study 10400838 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microgram budesonide once daily
Number of subjects: 309
Study 10400838 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram budesonide once daily (reduced to 200 microgram at week 6)
Number of subjects: 309
Study 10400838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 7724772 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (8 mumol Fe/kg)
Number of subjects: 33
Study 7724772 — intervention group
Group type: EXPERIMENTAL
Intervention: Resovist (4, 8, and 16 mumol Fe/kg)
Number of subjects: 33
Study 2066453 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 12
Study 6340009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine (1 g/day)
Number of subjects: 30
Study 6340009 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g/day)
Number of subjects: 30
Study 31232088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sound group
Number of subjects: 114
Study 31232088 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplug group
Number of subjects: 114
Study 31232088 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 30226143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya virus infection
Number of subjects: 509
Study 26739725 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred care (PCC)
Number of subjects: 478
Study 25316572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin (Suglat®)
Number of subjects: 0
Study 22985610 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg the night before surgery and 400 mg twice daily for 4 to 6 days post-surgery)
Number of subjects: 112
Study 22985610 — intervention group
Group type: COMPARATOR
Intervention: No amiodarone (control group)
Number of subjects: 112
Study 19785632 — intervention group
Group type: COMPARATOR
Intervention: Prone position during quiet sleep (QS)
Number of subjects: 31
Study 19785632 — intervention group
Group type: COMPARATOR
Intervention: Prone position during active sleep (AS)
Number of subjects: 31